His way: Greg Verdine is building a new kind of drug, with backing from a different kind of investor
After helping spearhead the launch of a long string of biotechs over the years from his prestigious perch at Harvard, Greg Verdine is now devoting …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
